DepYmed to Present Early Data on Its Small Molecule
PTP1B
Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting

2023-05-31

孤儿药

DepYmed to Present Early Data on Its Small Molecule

PTP1B

Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting

FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the

protein tyrosine phosphatase (PTP)

family of enzymes. Today DepYmed announces it will be presenting two abstracts on its small molecule PTP1B inhibitor

PTP1B

inhibitor program at the 2023 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting. The conference will be held June 5-7, 2023 at the Nashville Marriott at Vanderbilt University in Nashville, Tenn.

“This is a unique opportunity for us to present our mechanism-based approach to treating

Rett Syndrome

and to report progress on our lead clinical candidate at this important scientific forum. We believe our data continue to validate the potential of our compound for this devastating disease,” said Andreas Grill, DepYmed’s President and CEO. “We look forward to sharing these early data at the conference and with the wider scientific community.”

About IRSF

In 1983, a small, dedicated group of parents whose children had

Rett syndrome

formed the first non-profit to focus exclusively on

Rett syndrome

– the International Rett Syndrome Association (IRSA). In 2007, IRSA and Rett Syndrome Research Foundation (RSRF) consolidated resources to better serve families and maximize research investments toward a cure. The International Rett Syndrome Foundation (IRSF) emerged with a mission to accelerate research and empower families that builds upon these foundations’ pioneering work toward care and cure. empower families with information, knowledge, and connectivity. Today, the International

Rett Syndrome

Foundation continues its almost 40-year commitment to creating a world without Rett. It remains focused on accelerating research to treat and cure

Rett syndrome

as it seeks to empower families with information, knowledge, and connectivity.

About DPM-1003

Protein tyrosine phosphatases are major players in the control of cell signaling pathways that are disrupted in many diseases, yet no drug modulators of these enzymes have been successfully developed to date. DepYmed is the first company to develop a new class of orally bioavailable drug candidates that act by inhibiting

PTP1B

, one of the most important PTP drug targets. One of its lead compounds has shown promising efficacy in preclinical models of

Rett syndrome

, and the Company hopes to initiate a Phase 1 clinical trial in 2024. DPM-1003 has been granted Orphan Drug designation by the U.S. Food and Drug Administration and conditionally designated under the FDA’s Rare Pediatric Disease program.

About

Rett Syndrome

Rett syndrome

is a progressive

neurodevelopmental disorder

that almost exclusively affects females. Infants with

Rett syndrome

generally develop normally for 6 to 18 months after birth. At this point, they lose previously acquired skills (developmental regression) such as purposeful hand movements and the ability to communicate. Affected children often develop

autistic-like behaviors

breathing irregularities

feeding and swallowing difficulties

growth retardation

, and

seizures

. Most

Rett syndrome

cases are caused by mutations of the

MECP2

gene on the X chromosome and can present with a wide range of disability ranging from mild to severe. The expression of

PTP1B

, DepYmed’s target in

Rett syndrome

, is regulated by

MECP2

; in turn,

PTP1B

controls important cell functions that are disrupted in the disease.

About DepYmed, Inc.

DepYmed Inc., is a New York based rare disease and

cancer

therapeutic development company that was founded to capitalize on the scientific discoveries of the Tonks lab at Cold Spring Harbor Laboratory in the physiological function of

PTP1B

and ways to modulate its role in various human diseases. DepYmed is currently developing a new class of potent, orally bioavailable small molecule inhibitors of the enzyme

PTP1B

as novel therapeutics for

Rett Syndrome

and different types of

cancer

. In addition, DepYmed has also discovered a novel class of small molecules with copper chelating properties that it is developing as potential therapeutic agents for such diseases as

Wilson disease

and various

cancers

. The company is actively developing a deep pipeline of new compounds with broad therapeutic potential in these emerging drug classes in collaboration with Cold Spring Harbor Laboratory. For more information, please visit the Company’s website at: www.depymed.com.

For Media Inquiries please contact:

Jules Abraham

JQA Partners, Inc.

jabraham@jqapartners.com

917-885-7378

DepYmed:

info@depymedinc.com